Volume 5.40 | Oct 10

Mammary Cell News 5.40 October 10, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
To develop more effective breast cancer therapeutics and more readily understand their clinical impact, researchers constructed a functional metabolic portrait of 46 independently derived breast cell lines. Analysis of glutamine uptake and dependence identified a subset of triple-negative samples that are glutamine auxotrophs. [Cancer Cell] Abstract | Press Release
Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more - 645x110
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Notch3 Marks Clonogenic Mammary Luminal Progenitor Cells In Vivo
Using a conditionally inducible Notch3-CreERT2SAT transgenic mouse, researchers genetically marked Notch3-expressing cells throughout mammary gland development and followed their lineage in vivo. [J Cell Biol] Abstract

IBP-Mediated Suppression of Autophagy Promotes Growth and Metastasis of Breast Cancer Cells via Activating mTORC2/Akt/FOXO3a Signaling Pathway
Investigators report that upregulation of interferon regulatory factor-4 binding protein (IBP) expression significantly suppressed the autophagy of breast cancer cells, and downregulation of IBP expression markedly induced autophagy of these cells. [Cell Death Dis] Full Article

mTORC1/2 Targeted by n-3 Polyunsaturated Fatty Acids in the Prevention of Mammary Tumorigenesis and Tumor Progression
Four complementary and well-controlled animal models were utilized to identify the role and molecular target of n-3 polyunsaturated fatty acids in the prevention of breast carcinogenesis and progression. [Oncogene] Abstract

Signaling Events Mediated by α3β1 Integrin Are Essential for Mammary Tumorigenesis
Researchers showed that the deletion of α3β1 integrin, a major laminin receptor, from the basal layer of the mammary epithelium of K5ΔNβcat mice completely prevented the tumorigenesis induced by β-catenin signaling. [Oncogene] Abstract

Tumor Microenvironmental Signaling Elicits Epithelial-Mesenchymal Plasticity through Cooperation with Transforming Genetic Events
Investigators explore how extrinsic, tumor microenvironmental cytokines cooperate with intrinsic, genetic changes to promote epithelial-to-mesenchymal transition in human mammary epithelial cells. [Neoplasia]
Full Article

AMG 900, Pan-Aurora Kinase Inhibitor, Preferentially Inhibits the Proliferation of Breast Cancer Cell Lines with Dysfunctional p53
Researchers evaluated the in vitro activity of AMG 900 in a panel of 44 human breast cancer and immortalized cell lines and identify predictors of response. [Breast Cancer Res Treat] Abstract

Non-Overlapping Activities of ADF and Cofilin-1 During the Migration of Metastatic Breast Tumor Cells
Scientists investigated the roles of Actin Depolymerizing Factor (ADF) and cofilin-1 individually in the development of polarized migration of rat mammary adenocarcinoma cells. [BMC Cell Biol]
Abstract | Full Article

CLINICAL RESEARCH

A Phase II Study of Everolimus Combined with Trastuzumab and Paclitaxel in Patients with HER2-Overexpressing Advanced Breast Cancer that Progressed During Prior Trastuzumab and Taxane Therapy
In this phase II multicenter study, adult patients with HER2-positive advanced breast cancer resistant to trastuzumab and pretreated with a taxane received everolimus 10 mg/day in combination with paclitaxel (80 mg/m2 days 1, 8, and 15 every 4 weeks) and trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), administered in 28-day cycles. [Breast Cancer Res Treat] Full Article

Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
In this phase II multicenter trial, nab-paclitaxel and carboplatin were administered weekly with biweekly bevacizumab to 34 patients with first-line triple negative metastatic breast cancer. [Clin Breast Cancer] Abstract

Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
 
REVIEWS
Suitable Trial Designs and Cohorts for Preventive Breast Cancer Agents
Authors review past and current efforts in breast cancer chemoprevention in an attempt to explain why the field of breast cancer chemoprevention is progressing more slowly than was anticipated after early successes with tamoxifen. [Nat Rev Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
Department of Defense Grant Goes to University of Colorado Cancer Center
A major Department of Defense grant to researchers Jennifer Richer, PhD, and Anthony Elias, MD, at the University of Colorado Cancer Center aids development of drugs that target androgen receptors as a driver of breast cancer. [The Regents of the University of Colorado] Press Release

Rutgers Cancer Institute of New Jersey Researchers Awarded Nearly $2.5M to Examine Ways to Block Cancer Cell Growth
X.F. Steven Zheng, PhD was awarded a five-year $1.65 million grant from the National Institutes of Health (NIH) to examine an activating mechanism of the mTOR protein, which is a central controller of cell growth and metabolism. Darren R. Carpizo, MD, PhD, FACS was awarded a five-year grant from the NIH totaling $794,790. The funding will be utilized to further explore the effects of a compound identified in Dr. Carpizo’s laboratory that is found to restore tumor suppressor function of a mutated p53 gene in cancer cells. [Rutgers Cancer Institute of New Jersey] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2013 Canadian Cancer Research Conference
November 3-6, 2013
Toronto, Canada

NEW 31st Annual Miami Breast Cancer Conference 2014
March 6-9, 2014
Miami, United States

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Research Associate – Medical Epidemiology and/or Biostatistics (Karolinska Institutet)

NEW Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

NEW Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

Postdoctoral Position – Triple Negative Breast Cancer (Weizmann Institute of Science)

Postdoctoral Fellow – Nutritional Cancer Epigenetics (Purdue University)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Faculty Position – Management/Research of Hematologic, Breast, Head and Neck, Gastrointestinal, and Thoracic Medicine (Vanderbilt University Medical Center)

Vice President, Global Medical Affairs Position – Breast Disease (Celgene Corporation)

Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Mammary Cell News: Archives | Events | Contact Us